CellCentric Raises $26M to Advance Prostate Cancer Therapy Candidate CCS1477

CellCentric Raises $26M to Advance Prostate Cancer Therapy Candidate CCS1477
Biotechnology company CellCentric recently raised $26 million in private funding to advance clinical testing of its first-in-class therapy candidate CCS1477 as a treatment for prostate cancer. CCS1477 addresses the growing population of patients whose tumors have inherent or acquired resistance to second-generation androgen deprivation therapies through a different approach than current therapies that tackle resistance. The therapy candidate targets conserved domains in the p300 and CBP proteins, which are associated with cancer progression. When the two twin proteins are inhibited, expression of the main drivers of late-stage prostate cancer – including the androgen receptor (AR), related splice variants (AR-SV), and c-Myc – is significantly reduced. Particularly, reducing AR-SV is thought to mitigate the resistance that has been inherited or acquired to existing second-generation anti-androgen treatments like Zytiga (abiraterone), Xtandi (enzalutamide), and Erleada (apalutamide). The new p300/CBP inhibitor reprograms cancer cell growth in a way that distinguishes its action from other developmental agents. CCS1477 is now being developed as a treatment for late-stage castration-resistant prostate cancer, but eventually could be indicated for other cancer types. “There is a large and growing population of late-stage prostate cancer patients who have inherent or acquired resistance to current second-line anti-androgen therapies. CCS1477 has shown promise in addressing this. It is positioned
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *